Oral Proteins and Peptides Market Size, Share & Industry Analysis, By Drug Class (GLP-1 Peptides, Somatostatin Analogs, PTH Analogs, GLP-2 Peptides, and Others), By Therapeutic Area (Metabolic Disorders, Endocrine Disorders, and Others), By Age Group (Pediatric and Adult), By Formulation (Tablets and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and, Specialty Pharmacies & Others), and Regional Forecast, 2026-2034

Last Updated: April 28, 2026 | Format: PDF | Report ID: FBI116018

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 11.03% from 2026-2034
Unit	Value (USD Billion)
Segmentation	By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Region
By Drug Class	GLP-1 Peptides Somatostatin Analogs PTH Analogs GLP-2 Peptides Others
By Therapeutic Area	Metabolic Disorders Endocrine Disorders Others
By Age Group	Pediatric Adult
By Formulation	Tablets Others
By Distribution Channel	Hospital Pharmacies Retail Pharmacies & Drug Stores Specialty Pharmacies & Others
By Region	North America (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country) U.S. Canada Europe (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region) GCC South Africa Rest of Middle East & Africa